{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:18:44Z","timestamp":1768313924491,"version":"3.49.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Acute lymphoblastic leukemia (ALL) and lymphomas affect both pediatric and adult populations, therefore, they might be treated by pediatric or adult centers.It has been proven that the prognosis among adolescents and young adults (AYA) is poorer than among children, which remains a subject of research. Many factors are suspected to affect the diagnostic and treatment processes in adolescents and young adults, one of them being the organization of the healthcare system.The aimof the studywas to compare the time intervals between different events on disease trajectory in pediatric and AYA groups suffering from ALL and lymphomas.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We collected data on 81 patients diagnosed with ALL (50 children and 31 AYAs) and 100 patients diagnosed with lymphomas (50 children and 50 AYAs). Statistical analysis was performed in order to compare the groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The results confirmed the hypothesis that the duration of the diagnostic process differs significantly between groups. For patients with ALL, the analyzed time intervals were significantly shorter in the pediatric group than in the AYA group: first contact with a GP - admission to Hematology Department (2 vs. 5 days; pvalue= 0.004), first contact with a GP - treatment (6 vs. 12 days, p-value=0.001), diagnosis - treatment (1 vs. 3 days, p-value=0.003). In the case of patients suffering from lymphomas, the results were similar. The analyzed time intervals were significantly shorter in the pediatric group than in the AYA group: first contact with a GP- diagnosis (21 vs. 40.5 days, p-value&amp;lt;0.0001), first contact with a GP - treatment (27 vs. 65 days, p-value&amp;lt;0.0001). Trend analysis showed that the longer patients had presented symptoms before contacting the primary care physician, the longer they waited for the beginning of treatment both in ALL and lymphomas groups (p-values=0.0129 and 0.0038 respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>As the diagnostic and treatment processes are longer for AYA patients, actions must be undertaken in order to ensure equality and improve the healthcare system in Poland and possibly other countries.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1082789","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T08:11:55Z","timestamp":1675757515000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of diagnostic and treatment processes among pediatric and adolescents and young adults\u2019 populations suffering from acute lymphoblastic leukemia and lymphomas"],"prefix":"10.3389","volume":"13","author":[{"given":"Gazala","family":"Abdulaziz-Opiela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Sobieraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"P\u0142otka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Wi\u0119ckowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Derwich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3322\/caac.21219","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA: A Cancer J Clin"},{"key":"B2","unstructured":"National cancer institute"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.589","article-title":"Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum","volume":"2016","author":"Sandlund","year":"2016","journal-title":"Hematology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21637","article-title":"Cancer statistics for adolescents and young adults, 2020","volume":"70","author":"Miller","year":"2020","journal-title":"CA: A Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1089\/jayao.2021.0033","article-title":"Acute lymphoblastic leukemia in adolescents and young adults: A polish perspective","volume":"11","author":"Derwich","year":"2021","journal-title":"J Adolesc Young Adult Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100096","article-title":"Adolescents and young adults (AYA) with cancer: a position paper from the AYA working group of the European society for medical oncology (ESMO) and the European society for paediatric oncology (SIOPE)","volume":"6","author":"Ferrari","year":"2021","journal-title":"ESMO Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-18-0430","article-title":"Causes of inferior outcome in adolescents and young adults with acute lymphoblastic leukemia: Across oncology services and regardless of clinical trial enrollment","volume":"27","author":"Wolfson","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prevention: A Publ Am Assoc Cancer Research Cosponsored by Am Soc Prev Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1634\/theoncologist.11-6-590","article-title":"Cancer in 15- to 29-Year-Olds by primary site","volume":"11","author":"Bleyer","year":"2006","journal-title":"Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? a comparison of children\u2019s cancer group and cancer and leukemia group b studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.06.112","article-title":"Trends in survival for teenagers and young adults with cancer in the UK 1992\u20132006","volume":"51","author":"O\u2019Hara","year":"2015","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29669","article-title":"Case-linked analysis of clinical trial enrollment among adolescents and young adults at a national cancer institute-designated comprehensive cancer center","volume":"121","author":"Collins","year":"2015","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.36.2954","article-title":"Clinical trial participation and time to treatment among adolescents and young adults with cancer: Does age at diagnosis or insurance make a difference","volume":"29","author":"Parsons","year":"2011","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31127","article-title":"A prospective, observational cohort study comparing cancer clinical trial availability and enrollment between early adolescents\/young adults and children","volume":"124","author":"Thomas","year":"2017","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2096","article-title":"The effect of adopting pediatric protocols in adolescents and young adults with acute lymphoblastic leukemia in pediatric vs adult centers: AnIMPACTCohort study","volume":"8","author":"Gupta","year":"2019","journal-title":"Cancer Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-778530","article-title":"Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children","volume":"132","author":"Boissel","year":"2018","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30322","article-title":"Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study","volume":"123","author":"Muffly","year":"2016","journal-title":"Cancer"},{"key":"B17","article-title":"[Adolescents with acute lymphatic leukaemia achieve significantly better results when treated following Dutch paediatric oncology protocols than with adult protocols]","volume":"149","author":"de Bont","year":"2005","journal-title":"Nederlands Tijdschrift Voor Geneeskunde"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122912","article-title":"Management of aggressive non-Hodgkin lymphomas in the pediatric, adolescent, and young adult population: An adult vs. pediatric perspective","volume":"14","author":"Sheikh","year":"2022","journal-title":"Cancers"},{"key":"B19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1182\/asheducation-2007.1.297","article-title":"Should adolescents with NHL be treated as old children or young adults","volume":"2007","author":"Sandlund","year":"2007","journal-title":"Hematology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-778480","article-title":"Management of aggressive b-cell NHLs in the AYA population: an adult vs pediatric perspective","volume":"132","author":"Dunleavy","year":"2018","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194847","article-title":"Adolescent and young adult (AYA) cancer survivorship practices: An overview","volume":"13","author":"Janssen","year":"2021","journal-title":"Cancers"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1082789\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T08:12:03Z","timestamp":1675757523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1082789\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":21,"alternative-id":["10.3389\/fonc.2023.1082789"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1082789","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"article-number":"1082789"}}